



## RRPV Member Spotlight

SilverStream   
Medical

**Q: What does your company do? What specific capabilities or strengths does your company offer?**

**A:** [Silverstream Medical](#) offers a unique blend of established clinical success and specialized technical expertise in antimicrobial wound care. We are eager to offer the following capabilities to the RRPV community:

- **Proven Antimicrobial Technology:** Access to a proprietary, FDA 510(k) cleared platform that effectively destroys multi-drug-resistant biofilms without inducing tissue toxicity.
- **Rapid Scale-Up & Manufacturing:** Demonstrated ability to scale production six-fold within short timeframes, ensuring reliable supply chains for critical medical countermeasures.
- **Regulatory & Clinical Navigation:** Expertise in managing FDA (510k) and international regulatory pathways (CE) for life science products, supported by a management team with over three decades of medical device experience.
- **Global Distribution Infrastructure:** A well-established commercial network spanning 32 countries, providing a gateway for partners looking to expand their reach into emerging markets in Africa, Asia, and Latin America.
- **Specialized Veterinary Applications:** Advanced wound management capabilities for the veterinary sector through our Sil.Vet product line, suitable for animal wellness and surgical recovery research.
- **Trauma Support Advocacy:** A unique organizational commitment and experience in trauma care advocacy, bringing a deeply human-centric approach to medical innovation.

Our core products include:

- **Silverstream Solution:** Our flagship FDA 510(k) cleared liquid formulation. It utilizes a unique combination of low-concentration ionic silver in a buffered



hypertonic base to destroy biofilms and promote a healthy healing environment without the toxicity common in other silver-based products.

- Silverstream Gel: A high-viscosity version of our core technology designed for prolonged contact with the wound bed. It provides a sustained protective barrier while maintaining a moist healing environment.
- Sil.Vet: A specialized product line tailored for the veterinary market, providing the same high efficacy wound management for animal wellness and surgical recovery.
- Surgical Site Infection (SSI) Application: An advanced clinical application of our solution currently being validated for intraoperative irrigation to prevent post-surgical infections.

### Key Outcomes & Impact

- Clinical Efficacy: Demonstrated a 60% reduction in healing time for chronic wounds compared to standard care.
- Safety Profile: Our proprietary formulation achieves high antimicrobial activity at silver concentrations low enough to remain non-toxic to human tissue.
- Global Reach: Successfully scaled production to meet the needs of healthcare providers in 32 countries.

**Q: Are there any specific partnership opportunities you're seeking with other members in the industry? What kinds of expertise or resources would be beneficial for your company to explore through partnerships?**

**A:** Silverstream Medical is looking to collaborate with RRPV members who can provide complementary expertise to accelerate our US market entry and clinical validation. We are specifically seeking:

- Clinical Research Organizations (CROs): Partners with deep experience in managing multi-center clinical trials within the US, particularly those specializing in surgical outcomes and infection control.
- Government Contracting Specialists: Organizations or consultants with a proven track record in navigating the complexities of BARDA, DoD, and FEMA procurement and grant management.
- Advanced Manufacturing & Logistics: Partners capable of supporting high-volume sterile production or cold-chain logistics for medical devices within the United States.
- Wound Care & Orthopedic KOL Networks: Connection to surgeon-driven networks (particularly in orthopedics and trauma) to facilitate pilot programs and real-world evidence collection for our SSI prevention application.



- **Regulatory Affairs Expertise:** Specific expertise in navigating the transition from 510(k) cleared wound care devices to expanded surgical irrigation indications.

**Q: Provide some insight into your company's history, core business areas, focuses, or key ideas that you wish to describe.**

**A:** Silverstream Medical is an Israeli life science company founded on the mission to redefine wound management through advanced chemistry and patient-centric innovation. Led by a management team with over 30 years of experience in the medical device industry, the company has transitioned from a specialized research entity into a global provider of high-efficacy antimicrobial solutions.

### **Our Turnaround Story**

The current leadership team took a bold step in November 2021 by executing a management buyout during the height of the COVID-19 pandemic. At the time, the company was in a distressed state, but the founders recognized the untapped potential of its core technology. Since the buyout, the new leadership has successfully stabilized operations and taken Silverstream Medical to a completely different scale, expanding its regulatory footprint and commercial presence globally.

### **Core Business Areas & Focus**

- **Advanced Wound Care:** Our primary focus is the development of non-toxic, silver-ion based treatments that address the global crisis of antimicrobial resistance (AMR). Our technology is designed to eradicate biofilms, which are the leading cause of delayed healing in chronic wounds.
- **Surgical Safety:** We are currently expanding our core technology into the surgical suite. By developing protocols for intraoperative irrigation, we aim to set a new standard for the prevention of SSI.
- **Veterinary Medicine:** Through our Sil.Vet line, we apply the same advanced science to the animal health market, providing veterinarians with superior tools for wound and post-surgical care.
- **Global Health Security:** As an RRPV member, we focus on creating scalable medical countermeasures. Our ability to rapidly increase production makes us a vital partner for emergency preparedness and trauma response.
- **Key Philosophy:** At the heart of Silverstream Medical is the belief that advanced medical technology should be both highly effective and biologically gentle. We prioritize hypertonic activity and low-concentration silver to ensure that while pathogens are destroyed, healthy human tissue is preserved and encouraged to regenerate. This approach has led to our products being used in nearly 500,000 treatments across 32 countries, consistently delivering a 60% reduction in healing time for chronic wounds.



**Q: What trends or innovations do you foresee shaping the future of the industry, and how is your company preparing for those changes?**

**A:** As we look toward 2026 and beyond, Silverstream Medical is positioning itself at the intersection of several transformative industry trends:

- **Antimicrobial Stewardship (AMS) & The AMR Crisis:** With the World Health Organization identifying AMR as a top global threat, the industry is moving away from systemic antibiotics in favor of high-efficacy topical antiseptics. Silverstream is at the forefront of this shift, providing a non-antibiotic solution that destroys multi-drug-resistant biofilms without contributing to further resistance.
- **Proactive Infection Prevention (SSI):** The standard of care is shifting from reactive treatment to proactive, intraoperative prevention. We are preparing for this by validating our technology for surgical irrigation, aiming to stop SSI before they can take hold in the operating room.
- **Biofilm-Targeted Therapies:** Recent clinical data shows that over 80% of non-healing chronic wounds contain biofilms that evade traditional treatments. Our company is focused on the next generation of "biofilm-dissolving" agents, using our hypertonic, ionic silver formulation to physically disrupt these protective microbial structures.
- **Value-Based Healthcare & Remote Monitoring:** The industry is increasingly focused on clinical outcomes that reduce hospital readmissions. Silverstream's demonstrated 60% reduction in healing time directly supports this value-based model by getting patients out of the hospital faster and reducing the long-term cost of care.
- **Personalized & Precision Wound Care:** We see a future where wound care is tailored to the specific microbial signature of a patient's biofilm. Our ongoing research into new clinical applications, such as melanoma-associated wound healing, reflects our commitment to exploring how our technology can be part of personalized, complex treatment regimens.

**Q: How can we contact you?**

Eyal Nouri, CEO and Co-Founder  
[eyal@silverstreammed.com](mailto:eyal@silverstreammed.com)

Elya Presman, Co-Founder and Partner  
[elya@silverstreammed.com](mailto:elya@silverstreammed.com)



## Project Spotlight: Scaling Advanced Silver-Ion Technology for Global Surgical and Trauma Applications

### Q: Brief Description of the Project, Achievement, or Success Story.

**A:** Silverstream Medical is advancing a critical clinical initiative to transition our proven silver-ion wound care technology from chronic wound management into the surgical and trauma sectors. Our primary focus is a large-scale clinical program aimed at the prevention of SSI. By utilizing our FDA 510(k) cleared solution for intraoperative irrigation, we aim to significantly reduce infection rates in high-risk procedures.

This project represents a major "success story" in scaling Israeli life-science innovation for the US market. Following our successful participation in the Mass General Brigham (MGB) accelerator and our current expansion into the Boston biotech hub, we are now seeking to leverage this technology for rapid-response applications, including combat casualty care and biothreat-related wound management.

### Q: Key Outcome or Impact.

**A:** The primary impact of this initiative is the transformation of Silverstream from a specialized wound care solution into a broad-spectrum medical countermeasure capable of addressing complex surgical and trauma-related infections.

Key highlights include:

- **Global Scalability:** In 2025, Silverstream expanded its regulatory footprint to 32 countries, securing new approvals in markets such as Ukraine and Indonesia, and demonstrated the ability to scale production six-fold to meet international demand.
- **Commercial Momentum:** The company achieved nearly 200% revenue growth in 2025, providing a solid financial foundation for our expansion into the US surgical market.
- **Clinical Readiness:** By successfully joining the Mass General Brigham (MGB) accelerator, we have established the clinical infrastructure necessary to launch our \$5M initiative focused on SSI prevention.
- **Public Health Impact:** Once fully implemented in surgical settings, this project has the potential to drastically reduce post-operative complications and hospital readmissions, offering a cost-effective, non-antibiotic solution to the growing threat of AMR in surgical environments.



**Q: Collaborators or Partners for this Project.**

**A:** [Alliant Biotech](#): Delivers orthopedic solutions with a surgeon-driven approach, offering implants and biotechnology products grounded in two decades of research and patient care focus.